• Subscribe
  • Register for free Content
  • Cart
  • Login
  • Browse by Topic
    • Acamprosate
    • Addiction
    • Addiction Treatment
    • Addyi
    • Adhansia XR
    • ADHD
    • adolescents
    • Adult ADHD
    • Agitation
    • Akathisia
    • Alcohol
    • Alcohol Use
    • Alcohol use disorder
    • Alcoholism
    • Alternative treatments
    • amphetamine
    • Amphetamines
    • Anorexia Nervosa
    • Antidepressant Augmentation
    • Antidepressants
    • Antipsychotic
    • Antipsychotics
    • Anxiety
    • Anxiety Disorder
    • Aripiprazole
    • Asenapine
    • Assessment
    • attention
    • Attention Deficit Hyperactivity Disorder
    • Atypical Antipsychotics
    • Autism
    • Autism Spectrum Disorder
    • Autism Spectrum Disorder
    • Behavior therapy
    • Benzodiazepines
    • Bipolar Depression
    • Bipolar Disorder
    • Board Certification
    • Brain Devices
    • Brief psychotherapy
    • Bullying
    • Buprenorphine
    • Bupropion
    • Caffeine
    • CAM Treatments
    • Cannabidiol
    • Cannabis
    • Chantix
    • Child Psychiatry
    • Child Psychiatry
    • children
    • Clinical practice
    • CME Post-Test
    • Co-occurring disorders
    • Cognition
    • Cognitive Behavioral Therapy
    • Cognitive Decline
    • Cognitive Rehabilitation Therapy (CRT)
    • Collaborative care
    • Comorbidity
    • Complementary treatments
    • Complimentary treatments
    • Computers in Psychiatric Practice
    • Conduct Disorder
    • Confidentiality
    • Connect
    • Connection
    • Contagion
    • Cosmetic pharmacology
    • Crocus Sativus
    • Cultural Competence
    • Cymbalta
    • Dementia
    • Deplin
    • Deprescribing
    • Depression
    • Depressive Disorder
    • Diagnosis
    • Diagnostic Testing
    • DSM
    • Dual diagnosis
    • Duloxetine
    • Dysregulation
    • Eating Disorders
    • eCigarettes
    • Effexor
    • efficacy
    • Emotional dysregulation
    • End of Life Care
    • Engagement
    • Esketamine
    • eTNS
    • Existing marijuana
    • extended-release
    • Falls
    • Family Separation
    • FDA Warnings
    • Female hypoactive sexual desire disorder
    • Female Issues in Psychiatry
    • Folate
    • Folic Acid
    • Free Articles
    • Gender & Sexuality
    • Gender Dysphoria
    • Generalized Anxiety Disorder
    • GeneSight
    • Genetic Testing
    • Genetics and Psychiatry
    • Geriatric Psychiatry
    • Hair loss
    • Head Trauma
    • Health Apps
    • Heart rate
    • Hepatitis
    • HIPAA
    • Histamine
    • HIV
    • Hypnotics
    • Incarceration
    • Inflammation
    • inquiry
    • Insomnia
    • Intervention
    • Irritability
    • Ketamine
    • l-methylfolate
    • Laboratory Testing in Psychiatry
    • Learning & Developmental Disabilities
    • Light and Dark Therapy
    • Light therapy
    • Lightbox
    • Lithium
    • Low libido
    • Lyrica
    • Mania
    • Marijuana
    • Media
    • Medical Comorbidities
    • Medication
    • Medication adherence
    • Methadone
    • methylfolate
    • methylphenidate
    • Micronutrients
    • Mirtazapine
    • Mood Stabilizers
    • Motivational Interviewing
    • Naloxone
    • Naltrexone
    • Narcolepsy
    • Natural Medications
    • natural treatments
    • Neurology
    • Neuroscience in Psychiatry
    • Neurotoxicity
    • News of Note
    • Nightmares
    • Novel Medications
    • Nutrition
    • OCD
    • olanzapine
    • Opioid epidemic
    • Opioid Use Disorder
    • Opioids
    • Orthostasis
    • Outpatient
    • Overdose
    • Pain
    • Panic Disorder
    • Parenting Strategies
    • Patch
    • Patient relationship
    • pediatric
    • Personality Disorders
    • Pharmaceutical Industry
    • Pharmacology
    • Pharmacology Tips
    • PICOT
    • Pitolisant
    • Postpartum Depression
    • Potency
    • Practice Tools and Tips
    • Practice Tools and Tips
    • Prazosin
    • Pregabalin
    • Pregnancy
    • prescribing patterns
    • Prevention
    • Primary care
    • Prison
    • Prolonged exposure
    • Psychiatric interviewing
    • Psychopharm Myths
    • Psychopharmacology
    • Psychopharmacology Tips
    • Psychosis
    • Psychotherapy
    • Psychotherapy
    • PTSD
    • Registered Articles
    • Research
    • Research Update
    • Research Updates
    • Retirement
    • Risk
    • Risk Management
    • Risperidone
    • Ritalin
    • safety
    • Saffron
    • Saphris
    • Schizophrenia
    • School Refusal
    • Seasonal Affective Disorder
    • Secuado
    • Self-Regulation
    • Sex Therapy
    • Sexual Dysfunction
    • Sexual Side Effects
    • Side Effects
    • Sleep
    • Sleep Apnea
    • Sleep Disorders
    • Smoking Cessation
    • Smoking Cessation Agents
    • Social Anxiety Disorder
    • SSRIs
    • steroids
    • stimulant
    • Suboxone
    • Substance Abuse
    • Substance Abuse
    • Substance Use
    • Substance Use Disorder
    • Substance use disorders
    • Suicidality
    • Suicide
    • Symptom Assessment
    • Symptom Management
    • Technology
    • teens
    • test cme quiz
    • Therapy during medication appointment
    • Therapy with Med Management
    • TMS
    • Tobacco
    • Transcranial Magnetic Stimulation
    • Transdermal
    • Trauma
    • Traumatic Brain Injury (TBI)
    • treatment
    • treatment pediatric
    • Treatment planning
    • Treatment-Resistant Depression
    • Trigeminal Nerve Stimulation
    • Understanding Psychiatric Research
    • Vaping
    • Varenicline
    • Venlafaxine
    • Vyleesi
    • Wakix
    • Weed
    • Weight gain
    • Weight Loss Medications
    • Wellbutrin
    • Wilderness Therapy Programs
    • Withdrawal
    • Women's Issues in Psychiatry
    • Women’s Issues in Psychiatry
    • Working With Families
  • HOME
  • STORE
  • CME CENTER
  • Blog
  • NEWSLETTERS
    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
  • Archive
  • Archive
  • Archive
  • The Carlat Psychiatry Report
  • Topics in Neuropsychiatry (September)
  • Treating Headaches in Psychiatry

Treating Headaches in Psychiatry

The Carlat Psychiatry Report, Volume 7, Number 9, September 2009
https://www.thecarlatreport.com/newsletter-issue/tcprv7n9/

From The Carlat Psychiatry Report, September 2009, Topics in Neuropsychiatry

Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Topics: Free Articles | Natural Medications | Neuroscience in Psychiatry

Print Friendly, PDF & Email

Daniel Carlat, MD

We know that headaches are common in the general population, but they are particularly common among patients with psychiatric problems. According to one review, (Pompili M et al., J Headache Pain 2009; 10(4):283-290) patients with depression have a 46% lifetime prevalence of migraine, while bipolar patients have a 51% prevalence. Patients with migraines have triple the risk of developing depression than patients without migraines. In this article, we’ll review how to handle patients with headaches in a psychiatric practice. How do we distinguish migraine headaches from tension headaches from more dangerous secondary headaches that may be caused by a tumor or by hypertension? When should we refer headache patients to a neurologist? How should we treat these patients, both pharmacologically and psychotherapeutically? Diagnosis Textbooks will tell you that headaches come in essentially two varieties: primary (migraine, tension-type, and cluster) and secondary (caused by an underlying intracranial problem). While tension-type headaches (46% prevalence) are more common than migraines (25% prevalence), migraines are more likely to drive patients to seek medical attention, because they are usually more severe and debilitating. Migraine headaches are different from tension-type headaches in several ways. They are often unilateral rather than bilateral; they usually cause a throbbing, rather than a static pain; one third are associated with a prodromal aura; they often are accompanied by nausea and vomiting (so-called “sick headaches”); and patients often complain of photophobia, meaning that bright light makes the headache worse. In one study a simple three question screen was remarkably predictive of migraine. These three questions are: 1. Are you nauseated or sick to your stomach when you have a headache? 2. Have the headaches limited your activities for a day or more in the last three months? 3. Does light bother you when you have a headache? When two of these questions are answered “yes,” the positive predictive value for migraine was 93%; when all three were answered positively, the predictive value was 98% (Lipton RB et al., Neurology 2003;61:375-382). There’s a tendency among non-specialists to view tension-type headaches as being a waste-basket category for anything that is not a migraine, but in reality these headaches have fairly specific diagnostic criteria. According to the International Headache Society, tension- type headaches must meet at least two of the following criteria: 1. Pressing or tightening (nonpulsating) quality; 2. Mild to moderate intensity (meaning not so severe as to prohibit any normal activities); 3. Bilateral location; and 4. No aggravation from walking on stairs or similar activities. Furthermore, tension-type headaches must mean both of the following: 1. No nausea or vomiting; and 2. Only one of the following can be present: photophobia or phonophobia. Tension-type headaches typically last from 30 minutes to seven days. Patients will describe a “band of pain” extending from the forehead around both temples to the back of the head. Cluster headaches are rare and are described as an excruciating “boring” pain, often over one eye, lasting from 15 minutes to several hours. They may occur several times per day or night. I have a patient, a man in his early 30s with depression and OCD, who gets cluster headaches about once a year, and he is rendered completely out of commission for several weeks. The condition has played havoc with his ongoing efforts to complete a technical degree, and to move out of his parent’s house problems that, in turn, have complicated his psychiatric treatment. When should we refer to a neurologist? The short answer: almost always. Anybody who has severe or chronic headaches might have a secondary cause, and neurologists are experts at ruling this out. The workup will include a detailed neurologic exam, with an emphasis on the fundoscopic exam, and may or may not include a brain MRI, depending on the results of the exam and the neurologist’s judgment or philosophy. Medication Treatment Tension-type headaches. Once a secondary cause of a headache has been ruled out by a neurologist, psychiatrists are generally qualified to treat headache disorders, largely because of the great overlap between psychiatric drugs and headache drugs. For an episode of tension-type headaches, aspirin (500-1000 mg) and ibuprofen (400 mg) work well, and better than acetaminophen (1000 mg) (see Loder E and Rizzoli P, Brit Med J 2008; 336:88-92 for a good review of tensiontype headache management). When these over-the-counter meds don’t work, you can move on to bigger guns such as Fioricet, which is a combination of acetaminophen (325 mg), butalbital (50 mg), and caffeine (40 mg). Why is this triad of drugs so effective? Well, acetaminophen is a standard analgesic, butalbital is a barbiturate that relaxes the scalp’s muscle contractions, and caffeine relaxes blood vessels, improving blood flow to scalp muscles. Fioricet works for both tension and migraine headaches, but it is addictive and can cause intermittent headaches to convert to chronic headaches. Generally, when headaches become chronic, neurologists try to switch from “abortive” drugs (those that stop the headache in its tracks) to prophylactic drugs. The best prophylactic drug for chronic tension headaches is amitriptyline, usually dosed from 10 mg up to 75 mg one or two hours before bedtime; nortriptyline may be as effective, with fewer side effects. While the newer antidepressants such as the SSRIs and SNRIs are somewhat effective as well, they are not as effective as amitriptyline. Migraine headaches. Migraines come in many varieties, ranging from mild and rare to severe and frequent. I have had two migraines in my life. Each was triggered by looking briefly at the sun, and each began with a strange visual aura like hundreds of translucent overlapping gears spinning frenetically. The aura lasted about 15 minutes, followed by the onset of a pulsing left-sided headache. On each occasion, I took 600 mg of ibuprofen, and felt the need to lie down in a dark room. Within two hours or so, I recovered. I describe this case to illustrate the spectrum of migraines and their treatment. Anybody who presents themselves to a specialist will have had migraines far more severe and more frequent. While over-the-counter analgesics are effective for milder cases, often you need to ramp up treatment to drugs such as Fioricet, codeine, and various narcotics, all of which are considered acceptable treatments for the occasional migraine. But for more severe and frequent migraines, the preferred abortive treatments are triptans (such as sumitriptan and rizatriptan) which have replaced the ergots as the treatment of choice. There are now seven different triptans to choose from and each company will brandish studies to convince you theirs is best. Because of this complexity, neurologists are usually the better specialists to initiate treatment with a triptan. More important is for psychiatrists to know something about the controversy surrounding the safety of combining triptans with SSRIs. In 2006, the FDA issued an alert that combining triptans with either SSRIs or SNRIs can cause serotonin syndrome. The agency said this was based on 27 cases gathered over five years. The announcement was met widely with skepticism, because millions of patients had been combining triptans with SSRIs over the years and serotonin syndrome had rarely, if ever, been reported in the literature. Despite requests, the FDA has not made details of these 27 cases of supposed serotonin syndrome public, and a recent review concluded that “withholding these medications due to fears of serotonin syndrome is difficult to justify” (Wenzel R et al., Ann Pharmacother 2008;42(11):1692 -1696). Most of the drugs effective as prophylactics against migraines (as opposed to abortive drugs) are well known to psychiatrists, including amitriptyline, nortriptyline, Depakote (divalproex sodium), Neurontin (gabapentin), and Topamax (topiramate). Effective non-psychiatric prophylactic agents include the beta blockers propranolol and atenolol, and the calcium channel blocker verapamil. This is a good list to keep in mind for those “twofer” opportunities, such as when you are choosing something for a depressed patient with migraines (go with the tricyclics) or for a migraine patient with bipolar disorder (the obvious choice would be Depakote). Non-pharmacological Approaches While few psychiatrists will be investing in a biofeedback machine, this treatment may be the most effective nonpharmacological approach for headaches, especially tension-type headaches. One recent meta-analysis found that biofeed-back was more effective than headache monitoring, placebo, and relaxation therapies (Nestoriuc Y et al., J Consult Clin Psychol 2008;76:(3):379–396.) Headache clinics often have psychologists and psychiatrists on staff and they have developed techniques that you can incorporate into your practice for patients with comorbid depression or anxiety and migraine headaches. Called “behavioral medicine,” these are typically versions of cognitive behavioral therapy. The usual strategy is to determine how much the patient is allowing headache to limit activities, and to encourage them to “get back out there”, on the theory that they are inadvertently reinforcing their depressed mood through passivity. Help the patient make a list of enjoyable activities and come up with a graded schedule for re-engaging in life. Such techniques have been shown helpful in decreasing headache severity in some studies (Smitherman TA et al., Headache2007;48(1):45-50). Other techniques that have some empirical support for relief of chronic headaches include standard progressive muscle relaxation exercises and acupuncture.

TCPR Verdict:
Psychiatrists have a major role in headache treatment, ranging from psychopharmacology to psychotherapy.

 

 

 

 

Daniel Carlat, MD

Editor-in-Chief, Publisher, The Carlat Report. 

Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

Suggested Articles

  • Assessing and Treating Psychogenic Pain May 1, 2018
  • Is EEG Useful in Psychiatry? April 1, 2018
  • Neurofeedback in Psychiatry: What’s the Evidence? April 1, 2018
Share this page!
Subscribe
Register for free content

Register For Free Articles

Register to receive free email newsletters with concise, practical advice for busy clinicians. You will also have access to select article content on the website and you will receive notifications of new books and special discount offers.




Courses and Book CME
The Medication Fact Book for Psychiatric Practice, Fifth Edition (2020)
Carlat Report Binders - Organize Your Print Copies
Psychiatry Practice Boosters, Second Edition (2018)
2019 Carlat Psychiatry Report Self-Assessment Course
The Child Medication Fact Book for Psychiatric Practice (2018)
Issue Archives

2019

  • Depression (May)
  • Adult ADHD (November/December)
  • Mental Health Apps (October)
  • How to Talk about Medication (September)
  • Side Effects Part II (August)
  • Side Effects Part I (June/July)
  • Sleep (April)
  • Parenting, Pregnancy, and Prevention (March)
  • Dark and Light Therapy (February)
  • Deprescribing (January)

2018

  • Drug Metabolism (November/December)
  • Working With Transgender Patients (October)
  • Emergency Psychiatry (September)
  • Treatment-Resistant Depression (July/August)
  • Neurobiology (June)
  • Anxiety (May)
  • Neurofeedback (April)
  • Antipsychotics Update (March)
  • Working With Families (February)
  • Bipolar Disorder (January)

2017

  • PTSD (December)
  • Retirement (November)
  • Intellectual Disability (September/October)
  • Antidepressants (July/August)
  • Personality Disorders (June)
  • Dementia (May)
  • Cognitive Behavior Therapy Techniques (April)
  • Pharmacogenetics (March)
  • Treating Psychosis (February)
  • Adult ADHD (January)

2016

  • Complementary and Alternative Medicine in Psychiatry (November/December)
  • Side Effects (October)
  • Pain Management (September)
  • Medication in Pregnancy (July/August)
  • Psychoanalysis in Modern Psychiatry (June)
  • Correctional Psychiatry (May)
  • Antidepressant Roundup (April)
  • Burnout (March)
  • Private Practice (February)
  • Bipolar Disorder (January)

2015

  • Psychiatry and General Medicine (November/December)
  • Biomarkers in Psychiatry (May)
  • Telepsychiatry (October)
  • Sleep Disorders (September)
  • Interventional Psychiatry (July/August)
  • Eating Disorders (June)
  • Psychotherapy Updates (April)
  • Topics in Geriatric Psychiatry (March)
  • Antipsychotics Update (February)
  • Risk Management (January)

2014

  • Bipolar Disorder (November/December)
  • Pharmacogenetics (October)
  • Keeping up in Psychiatry (September)
  • Research in Psychiatry (July/August)
  • Marijuana (June)
  • Psychiatric Diagnosis (May)
  • Issues in Psychopharmacology (April)
  • Schizophrenia (March)
  • Women’s Psychiatry (February)
  • Ethics in Psychiatry (January)

2013

  • Military Psychiatry (December)
  • Depression (November)
  • Treatment of Dementia (October)
  • Anxiety Disorders (September)
  • Natural and Alternative Treatments in Psychiatry (July/August)
  • Autism Spectrum Disorder (June)
  • Practice Tips (May)
  • Substance Abuse (April)
  • Medicolegal Topics (March)
  • End of Life Care (February)
  • Antipsychotic Update (January)

2012

  • Screening Tools and Tips (December)
  • Medical Comorbidities (November)
  • Devices in Psychiatry (October)
  • Eating Disorders (September)
  • Bipolar Disorder (July/August)
  • Risk Management (June)
  • Antidepressant Roundup 2012 (May)
  • Gender and Sexuality (April)
  • Personality Disorders (March)
  • ADHD (February)
  • Natural Treatments in Psychiatry (January)

2011

  • Electronic Medical Records (December)
  • Insomnia (November)
  • Psychotherapy (October)
  • Alcoholism (September)
  • Anxiety Disorders (July/August)
  • Schizophrenia (June)
  • Managing Side Effects (May)
  • Antidepressant Roundup 2011 (April)
  • DSM-5 and Diagnostic Issues (March)
  • Drug-Drug Interactions (February)
  • Bipolar Disorder (January)

2010

  • Hospital Psychiatry (December)
  • Psychiatric Medication in Pregnancy (November)
  • Maintenance of Certification (October)
  • The Neuroscience of Psychotherapy (September)
  • Treatment of Depression (July/August)
  • Email and the Internet in Psychiatry (June)
  • Substance Abuse (May)
  • The Diagnosis and Treatment of Dementia (April)
  • Ethics in Psychiatry (March)
  • Natural Treatments in Psychiatry (February)
  • ADHD (January)

2009

  • Treating Schizophrenia (December)
  • Treatment for Anxiety Disorders (November)
  • The Latest on Antidepressants (October)
  • Topics in Neuropsychiatry (September)
  • The Interface of Medicine and Psychiatry (July/August)
  • Generic Medications in Psychiatry (June)
  • The Treatment of Eating Disorders (May)
  • Healthcare Policy and Psychiatry (April)
  • Antipsychotic Roundup 2009 (March)
  • Psychiatric Medication in Pregnancy and Lactation (February)
  • Transcranial Magnetic Stimulation (January)

2008

  • Treating Fibromyalgia and Pain in Psychiatry (December)
  • Issues in Child Psychiatry (November)
  • Improving Psychiatric Practice (October)
  • Treating Personality Disorders (September)
  • Bipolar Disorder (July/August)
  • Antipsychotic Roundup 2008 (June)
  • Atypical Antipsychotics in Clinical Practice (February)
  • Neuropsychological Testing (May)
  • Psychiatric Medications: Effects and Side Effects (April)
  • Update on Substance Abuse (March)
  • Anticonvulsants in Psychiatry (February)
  • Brain Devices in Psychiatry (January)

2007

  • The Treatment of Insomnia (December)
  • Avoiding Malpractice in Psychiatry (November)
  • Update on Eating Disorders (October)
  • Complex Psychopharmacology (September)
  • Laboratory Testing in Psychiatry (August)
  • Psychotherapy in Psychiatry (July)
  • Posttraumatic Stress Disorder (June)
  • Topics in Geriatric Psychiatry 2007 (May)
  • Pregnancy and Menopause in Psychiatry (Apil)
  • Antipsychotic Roundup 2007 (March)
  • Understanding Psychiatric Research (February)
  • Antidepressant Round-up 2007 (January)

2006

  • Technology and Psychiatric Practice (December)
  • The Use of MAOIs (November)
  • Medication Treatment of Depression (January)
  • Seasonal Affective Disorder (October)
  • Treatment of ADHD (September)
  • Topics in Bipolar Disorder (August)
  • Neurotransmitters in Psychiatry (July)
  • Treating Substance Abuse (June)
  • The STAR*D Antidepressant Trial (May)
  • Natural Treatments in Psychiatry (April)
  • Medication Treatment of Anxiety (March)
  • Panic Disorder: Making Treatment Work (March)
  • Antipsychotic Roundup 2006 (February)
  • Antidepressant Roundup 2006 (January)

2005

  • Self-Help Books and Psychiatry (December)
  • Genetics and Psychiatry (November)
  • Pregnancy and Psychiatric Treatment (October)
  • Benzodiazepines and Hypnotics in Psychiatry (September)
  • Geriatric Psychiatry Update (August)
  • Chart Documentation in Psychiatry (July)
  • The Treatment of Bipolar Disorder (June)
  • Weight Loss and Smoking Cessation in Psychiatry (May)
  • Treating ADHD (April)
  • Drug Industry Influence in Psychiatry (March)
  • Atypical Antipsychotics 2005 (February)
  • Antidepressant Roundup 2005 (January)

2004

  • Sexual Dysfunction (December)
  • Suicide Prevention (November)
  • To Sleep, To Awake (October)
  • Women’s Issues in Psychiatry (September)
  • OCD: An Update (August)
  • Chronic Pain and Psychiatry (July)
  • Neuroimaging in Psychiatry (June)
  • Natural Medications in Psychiatry (May)
  • Posttraumatic Stress Disorder (April)
  • Treatment of Alcoholism (March)
  • Battle of the Atypicals (February)
  • Antidepressant Roundup, 2004 (January)

2003

  • Research Methods in Psychiatry (December)
  • Antidepressants in Children (November)
  • The Treatment of Dementia (October)
  • Bipolar Disorder, Part II: The Novel Anticonvulsants (September)
  • Bipolar Disorder: The Basics (August)
  • Drug-Drug Interactions in Psychiatry (July)
  • Managing Antidepressant Side Effects (June)
  • Antidepressants in Pregnancy and Lactation (May)
  • ADHD: Medication Options (April)
  • Panic Disorder: Making Treatment Work (March)
  • Atypical Antipsychotics in Clinical Practice (February)
  • Medication Treatment of Depression (January)

2018

  • Psychotropic Risks in Children and Adolescents (May/June)
  • ADHD in Children and Adolescents (November/December)
  • Depression in Children and Adolescents (September/October)
  • Autism in Children and Adolescents (July/August)
  • Anxiety in Children and Adolescents (March/April)
  • Suicide in Children and Adolescents (January/February)

2017

  • Adolescents (November/December)
  • ADHD in Children and Adolescents (September/October)
  • Psychosis in Children and Adolescents (August)
  • PANDAS, PANS, and Related Disorders (June/July)
  • Marijuana in Children and Adolescents (May)
  • Tourette’s and Other Tic Disorders in Children and Adolescents (March/April)
  • Autism in Children and Adolescents (January/February)

2016

  • Gender Dysphoria in Children and Adolescents (November/December)
  • Technology Issues With Children and Adolescents (September/October)
  • Mood Dysregulation in Children and Adolescents (July/August)
  • Eating Disorders in Children and Adolescents (May/June)
  • Conduct Disorder in Children and Adolescents (April)
  • Sleep Disorders in Children and Adolescents (March)
  • ADHD in Children and Adolescents (January/February)

2015

  • Antidepressant Use in Children (November/December)
  • Foster Care and Child Psychiatry (September/October)
  • Autism (July/August)
  • Trauma (May/June)
  • Anxiety Disorders (April)
  • Schools and Psychiatry (March)
  • Emergency Psychiatry in Children (January/February)

2014

  • Antipsychotics in Children (December)
  • ADHD (November)
  • Gender and Sexuality (September/October)
  • Psychotic Symptoms (Summer)
  • Medication Side Effects (May)
  • Food and Mood (April)
  • Learning and Developmental Disabilities (February)

2013

  • Complex Practice Issues (December)
  • Diet and Nutrition (November)
  • Child Psychiatry in DSM-5 (August/September)
  • Medication Side Effects and Interactions (June/July)
  • Problematic Technology (March/April)
  • Autism Spectrum Disorders (January/February)

2012

  • Bipolar Disorder (December)
  • Substance Abuse (October/November)
  • Transitional Age Youth (July/August)
  • Rating Scales (May/June)
  • Eating Disorders (March/April)
  • Behavioral Disorders (February)

2011

  • Treatment of Anxiety Disorders (December)
  • Trauma (November)
  • Bullying and School Issues (October)
  • Hidden Medical Disorders (August)
  • OCD and Tic Disorders (June)
  • Suicide and Non-Suicidal Self Injury (April)
  • Sleep Disorders (March)
  • ADHD (January)

2010

  • Use of Antipsychotics in Children and Adolescents (December)
  • Learning and Developmental Disabilities (October)
  • Major Depression (September)
  • Treating Children and Families (July)
  • The Explosive Child (May)

2018

  • Opioid Addiction (November/December)
  • Addiction in Older Adults (October)
  • Sleep Disorders and Addiction (September)
  • Adolescent Addiction (July/August)
  • Pain and Addiction (May/June)
  • Cannabis and Addiction (March/April)
  • Stigma and Addiction (January/February)

2017

  • Pregnancy and Addiction (November/December)
  • Detox (Sepember/October)
  • Dual Diagnosis (August)
  • Alternatives to 12-Step Programs (June/July)
  • Recovery (May)
  • Psychiatric Uses of Street Drugs (March/April)
  • Sex Addiction (January/February)

2016

  • Prescription Drug Monitoring Programs (PDMPs) (November/December)
  • Addiction in Health Care Professionals (September/October)
  • Dialectical Behavior Therapy in Addiction (August)
  • Motivational Interviewing (June/July)
  • Benzodiazepines (May)
  • Opioid Addiction (March/April)
  • Families and Substance Abuse (January/February)

2015

  • The Twelve Steps (November/December)
  • Designer Drugs (September/October)
  • Residential Treatment Programs Decoded (July/August)
  • Nicotine and E-Cigarettes (June)
  • Drug Screening (April/May)
  • Integrating Therapy and Medications for Alcoholism (March)
  • Detoxification Protocols (January/February)

2014

  • Behavioral Addictions (December)
  • Risk and Reimbursement (November)
  • Stimulant Abuse (September/October)
  • Self-Help Programs (June)
  • Opioid Addiction (May)
  • Coping with Bad Outcomes (March)
  • Change Management in Addiction Treatment (January/February)

2013

  • Cocaine Addiction (December)
  • Relapse Prevention (November)
  • Cannabis Addiction (August/September)
  • Addiction in DSM-5 (June/July)
Editor-in-Chief

Chris Aiken, MD

Dr. Aiken is the director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice.

Full Editorial Information

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Subscriptions
  • Books
  • Online Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Child Psychiatry Report

Contact

  • info@thecarlatreport.com
  • 866-348-9279
  • PO Box 626, Newburyport MA 01950

Follow Us

© 2019 Carlat Publishing, LLC and Affiliates, All Rights Reserved.

Please see our Privacy Policy and the Hardware/Software Requirements to view our website.